Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Monday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on CLLS. JMP Securities reissued a market outperform rating and issued a $6.00 price target on shares of Cellectis in a report on Friday, May 31st. Oppenheimer cut their target price on shares of Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research note on Wednesday, June 12th.

Cellectis Price Performance

Shares of Cellectis stock opened at $2.01 on Monday. The firm has a market cap of $111.72 million, a PE ratio of -1.56 and a beta of 3.10. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.69. The company’s fifty day simple moving average is $2.50 and its two-hundred day simple moving average is $2.67.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $6.50 million during the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. As a group, equities analysts expect that Cellectis will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Baillie Gifford & Co. boosted its holdings in shares of Cellectis S.A. (NASDAQ:CLLS) by 1.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 827,248 shares of the biotechnology company’s stock after acquiring an additional 10,605 shares during the period. Baillie Gifford & Co. owned 1.49% of Cellectis worth $2,192,000 at the end of the most recent reporting period. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.